Supported by phase 3 OASIS-4 data, elinzanetant significantly reduced daily hot flash frequency in women receiving endocrine therapy for HR-positive breast cancer.
Phase 3 trial data show significant scalp, eyelash, and eyebrow hair regrowth at 36 weeks in adolescents treated with oral baricitinib.
Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.
Advisers split on whether Galleri, which screens for more than 50 cancers, catches disease early enough to save lives.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results